Secondary CV Prevention in South America in a Community Setting: The PURE Study

Global Heart

Volumn 12, Issue 4, 2017, Pages 305-313

  Avezum, Alvaro ^a   Oliveira, Gustavo B F ^a   Lanas, Fernando ^b   Lopez Jaramillo, Patricio ^c   Diaz, Rafael ^d   Miranda, J Jaime ^e   Seron, Pamela ^b   Camacho Lopez, Paul A ^c   Orlandini, Andres ^d   Bernabe Ortiz, Antonio ^e   Cordeiro Mattos, Antônio ^a   Islam, Shofiqul ^f   Rangarajan, Sumathy ^f   Teo, Koon ^f   Yusuf, Salim ^f  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

^c UNIVERSIDAD DE SANTANDER   (Colombia)

^d Instituto Cardiovascular de Rosario   (Argentina)

^e UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; AGED; ANGINA PECTORIS; ARGENTINA; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMMUNITY CARE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; DUAL ANTIPLATELET THERAPY; EDUCATIONAL STATUS; EVIDENCE BASED PRACTICE; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LOW INCOME COUNTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE INCOME COUNTRY; OBESITY; PRIORITY JOURNAL; QUESTIONNAIRE; RURAL POPULATION; SECONDARY PREVENTION; SELF REPORT; SOUTH AMERICA; STROKE PATIENT; URBAN POPULATION; AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEVELOPING COUNTRY; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; SEX RATIO; TRENDS;

ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEVELOPING COUNTRIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; PROSPECTIVE STUDIES; RURAL POPULATION; SECONDARY PREVENTION; SEX DISTRIBUTION; SOUTH AMERICA; URBAN POPULATION;

EID: 85003602686     PISSN: 22118160     EISSN: 22118179     Source Type: Journal    
DOI: 10.1016/j.gheart.2016.06.001     Document Type: Article

References (56)

1. Pan American Health Organization. Regional Health Observatory: Indicadores Básicos de Salud: Mortalidad: Causas principales de defunción 2010. Available at: http://ais.paho.org/phip/viz/mort_causasprincipales_lt_oms.asp. Accessed in January 1, 2016.
2. Avezum, A., Costa-Filho, F.F., Pieri, A., Martins, S.O., Marin-Neto, J.A., Stroke in Latin America: burden of disease and opportunities for prevention. Glob Heart 10 (2015), 323–331.
3. Yusuf, S., Reddy, S., Ounpuu, S., Anand, S., Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 (2001), 2746–2753.
4. GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
5. Global Burden of Disease Study 2013 Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
6. Yusuf, S., Peto, R., Lewis, J., Collins, R., Sleight, P., Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985), 335–371.
7. Dagenais, G.R., Pogue, J., Fox, K., Simoons, M.L., Yusuf, S., Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006), 581–588.
8. Baigent, C., Blackwell, L., Emberson, J., et al., for the Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
9. Antiplatelet Trialists' Collaboration, Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994), 81–106.
10. Yusuf, S., Two decades of progress in preventing vascular disease. Lancet 360 (2002), 2–3.
11. Perel, P., Avezum, A., Huffman, M., et al. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation Roadmap for secondary prevention of cardiovascular disease. Glob Heart 10 (2015), 99–110.
12. Cabral, N.L., Franco, S., Longo, A., et al. The Brazilian Family Health Program and secondary stroke and myocardial infarction prevention: a 6-year cohort study. Am J Public Health 102 (2012), e90–e95.
13. Gaziano, T.A., Bilton, A., Anand, S., Abrahams-Gessel, S., Murphy, A., Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 35 (2010), 72–115.
14. Yusuf, S., Rangaragan, S., Teo, K., et al., for the PURE Investigators. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 371 (2014), 818–827.
15. Yusuf, S., Islam, S., Chow, C.K., et al., for the PURE Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 378 (2011), 1231–1243.
16. Teo, K., Chow, C.K., Vaz, M., et al., for the PURE Investigators Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 158 (2009), 1–7 e1.
17. Yusuf, S., Hawken, S., Ounpuu, S., et al., for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
18. O'Donnell, M.J., Xavier, D., Liu, L., et al., for the INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376 (2010), 112–123.
19. Sacco, R.L., Adams, R., Albers, F., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006), 577–617.
20. Kotseva, K., Wood, D., De Backer, G., et al., for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373 (2009), 929–940.
21. Tsang, J.L., Mendelsohn, A., Tan, M.K., et al., for the Vascular Protection Registry and Guidelines Oriented Approach to Lipid Lowering Registry Investigators. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy. Am J Cardiol 102 (2008), 1142–1145.
22. Lopez-Carmona, D., Bernal-Lopez, M., Mancera-Romero, J., et al. Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study. Eur J Prev Cardiol 19 (2012), 1074–1081.
23. Naderi, S.H., Bestwick, J.P., Wald, D.S., Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125 (2012), 882–887 e1.
24. Kronish, I.M., Diefenbach, M.A., Edmondson, D.E., Phillips, L.A., Fei, K., Horowitz, C.R., Key barriers to medication adherence in survivors of strokes and transient ischemic attacks. J Gen Intern Med 28 (2013), 675–682.
25. Osterberg, L., Blaschke, T., Adherence to medication. N Engl J Med 353 (2005), 487–497.
26. Rodriguez, F., Cannon, C.P., Steg, P.G., et al., for the REACH Registry Investigators. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH registry. Clin Cardiol 36 (2013), 721–727.
27. Kumbhani, D.J., Stef, P.G., Cannon, C.P., et al., for the Reduction of Atherothrombosis for Continued Health Registry Investigators. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med 126 (2013), 693–700 e1.
28. Mendis, S., Abegunder, D., Yusuf, S., et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 83 (2005), 820–829.
29. Cole, J.A., Brennan, A.L., Ajani, A.E., et al. Cardiovascular medication use following percutaneous coronary intervention: the Australian experience. Cardiovasc Ther 32 (2014), 47–51.
30. Nazzal, C., Lanas, F., Garmendia, M.L., et al. (Trans.) Universal health coverage and accomplishment of secondary prevention goals among patients with acute myocardial infarction Rev Med Chil 141 (2013), 977–986.
31. Kerr, A., Exeter, D., Hanham, G., et al. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1). N Z Med J 127 (2014), 39–69.
32. Cabana, M.D., Rand, C.S., Powe, N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999), 1458–1465.
33. van Mourik, M.S., Cameron, A., Ewen, M., Laing, R.O., Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord, 10, 2010, 25.
34. Niens, L.M., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W.B., Laing, R., Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med, 7, 2010 pii:e1000333.
35. Rajpura, J., Nayak, R., Medication adherence in a sample of elderly suffering from hypertension: evaluating the influence of illness perceptions, treatment beliefs, and illness burden. J Manag Care Pharm 20 (2014), 58–65.
36. Murray, K.A., Murphy, D.J., Clements, S.J., Brown, A., Connolly, S.B., Comparison of uptake and predictors of adherence in primary and secondary prevention of cardiovascular disease in a community-based cardiovascular prevention programme (MyAction Westminster). J Public Health (Oxf) 36 (2014), 644–650.
37. Eissa, A., Krass, I., Bajorek, B.V., Use of medications for secondary prevention in stroke patients at hospital discharge in Australia. Int J Clin Pharm 36 (2014), 384–393.
38. Bangalore, S., Schwamm, L., Smith, E.E., et al., for the Get With the Guidelines–Stroke Steering Committee and Investigators. Secondary prevention after ischemic stroke or transient ischemic attack. Am J Med 127 (2014), 728–738.
39. Ostergaard, K., Madsen, C., Liu, M.L., Bak, S., Hallas, J., Gaist, D., Long-term use of antiplatelet drugs by patients with transient ischaemic attack. Eur J Clin Pharmacol 70 (2014), 241–248.
40. Heuschmann, P.U., Kircher, J., Nowe, T., et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Prev Cardiol 22 (2015), 1354–1362.
41. Bejot, Y., Zeller, M., Lorgis, L., et al. Secondary prevention in patients with vascular disease: a population based study on the underuse of recommended medications. J Neurol Neurosurg Psychiatry 84 (2013), 348–353.
42. Glader, E.L., Sjolander, M., Eriksson, M., Lundberg, M., Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 41 (2010), 397–401.
43. Canavero, I., Cavallini, A., Perrone, P., et al., for the Lombardi Stroke Registry Investigators. Clinical factors associated with statins prescription in acute ischemic stroke patients: findings from the Lombardia Stroke Registry. BMC Neurol, 14, 2014, 53.
44. Li, X., Gao, Y., Li, J., et al., for the HPS2-THRIVE China Group. Underuse of statins in patients with atherosclerotic ischemic stroke in China. Chin Med J (Engl) 125 (2012), 1703–1707.
45. Tsai, J.P., Rochon, P.A., Raptis, S., Bronskill, S.E., Bell, C.M., Saposnik, G., A prescription at discharge improves long-term adherence for secondary stroke prevention. J Stroke Cerebrovasc Dis 23 (2014), 2308–2315.
46. Lewey, J., Shrank, W.H., Bowry, A.D., Kilabuk, E., Brennan, T.A., Choudhry, N.K., Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 165 (2013), 665–678 e1.
47. Halava, H., Korhonen, M.J., Huupponen, R., et al. Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. CMAJ 186 (2014), E449–E456.
48. Su, Q., Yuan, K., Long, F., et al. Evaluation on the compliance with secondary prevention and influence factors of ischemic stroke in Hainan Province, China. Vascular 22 (2014), 181–187.
49. Gandhi, S., Dorian, P., Greenlaw, N., et al., for the Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease CLARIFY Registry Investigators. Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. Can J Cardiol 30 (2014), 132–137.
50. Rasella, D., Harhay, M.O., Pamponet, M.L., Aquino, R., Barreto, M.L., Impact of primary health care on mortality from heart and cerebrovascular diseases in Brazil: a nationwide analysis of longitudinal data. BMJ, 349, 2014, g4014.
51. Rubinstein, A., Rubinstein, F., Botargues, M., Kopitowski, K., A multimodal strategy based on pay-per-performance to improve quality of care of family practitioners in Argentina. J Ambul Care Manage 32 (2009), 103–114.
52. West-Pollak, A., Then, E.P., Podesta, C., et al. Impact of a novel community-based lifestyle intervention program on type 2 diabetes and cardiovascular risk in a resource-poor setting in the Dominican Republic. Int Health 6 (2014), 118–124.
53. Yuasa, M., de Sa, R.F., Pincovsky, S., Shimanouchi, N., Emergence Model of social and human capital and its application to the Healthy Municipalities project in Northeast Brazil. Health Promot Int 22 (2007), 292–298.
54. Huffman, M.D., Perel, P., Beller, G.A., et al. World Heart Federation Emerging Leaders Program: an innovative capacity building program to facilitate the 25 x 25 goal. Glob Heart 10 (2015), 229–233.
55. Yusuf, S., Wood, D., Ralston, J., Reddy, K.S., The World Heart Federation's vision for worldwide cardiovascular disease prevention. Lancet 386 (2015), 399–402.
56. Corsi, D.J., Subramanian, S.V., Chow, C.K., et al. Prospective Urban Rural Epidemiology (PURE) study: baseline characteristics of the household sample and comparative analyses with national data in 17 countries. Am Heart J 166 (2013), 636–646 e4.